Literature DB >> 8379668

[Pharmacokinetics in arterial infusion chemotherapy].

Y Arai1, C Kido, Y Ariyoshi.   

Abstract

The pharmacokinetics of arterial infusion chemotherapy was introduced. The pharmacokinetic rationales were based on the theories of "first pass effect" and "increased local concentration without first pass effect" advocated by Dr. Collins. These theories can offer much information to select the drug and to determine the administration schedule. However, for most of the drugs, the clinical pharmacokinetic studies are poor, and the optimal dose in bolus intraarterial infusion and the administration schedule is uncertain in terms of the dosage and hours. There are also some differences between pharmacokinetic understanding and clinical effect. Thus, further pharmacokinetic investigations and clinical studies are required to establish effective regimens for arterial infusion chemotherapy.

Mesh:

Substances:

Year:  1993        PMID: 8379668

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods.

Authors:  Feng Qian; Nicholas Stowe; Gerald M Saidel; Jinming Gao
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

2.  High Response Rate and Prolonged Survival of Unresectable Biliary Tract Cancer Treated With a New Combination Therapy Consisting of Intraarterial Chemotherapy Plus Radiotherapy.

Authors:  Takuma Goto; Hiroya Saito; Junpei Sasajima; Toru Kawamoto; Akihiro Fujinaga; Tatsuya Utsumi; Nubuyuki Yanagawa; Kazuhide Hiramatsu; Akio Takamura; Hiroki Sato; Shugo Fujibayashi; Mikihiro Fujiya
Journal:  Front Oncol       Date:  2020-11-17       Impact factor: 6.244

3.  DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC.

Authors:  Yasuteru Kondo; Tatsuki Morosawa; Soichiro Minami; Yasuhito Tanaka
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.